The committee will discuss the NDA submitted by Forest (now Activis) for nebivolol/valsartan fixed-dose combination tablets (5/80 milligrams (mg), 5/160 mg, 10/160 mg, 10/320 mg and 20/320 mg), submitted by Forest Laboratories, Inc., for the proposed indication of the treatment of hypertension.